Insider Transactions in Q2 2024 at Gilead Sciences, Inc. (GILD)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,662
-1.2%
|
$108,030
$65.25 P/Share
|
|
Jun 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,639
+2.56%
|
-
|
|
Jun 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,693
-0.95%
|
$305,045
$65.25 P/Share
|
|
Jun 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,295
+2.04%
|
-
|
|
Jun 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
255
-0.76%
|
$16,575
$65.25 P/Share
|
|
Jun 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
901
+2.62%
|
-
|
|
Jun 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,744
-1.74%
|
$113,360
$65.25 P/Share
|
|
Jun 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,820
+3.68%
|
-
|
|
Jun 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,714
-1.4%
|
$111,410
$65.25 P/Share
|
|
Jun 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,751
+2.98%
|
-
|
|
Jun 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-1.38%
|
$13,260
$65.25 P/Share
|
|
Jun 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
638
+4.15%
|
-
|
|
May 08
2024
|
Jacqueline K Barton Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+8.6%
|
-
|
|
May 08
2024
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+45.01%
|
-
|
|
May 08
2024
|
Javier Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+17.75%
|
-
|
|
May 08
2024
|
Anthony Welters Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+18.42%
|
-
|
|
May 08
2024
|
Harish Manwani Director |
SELL
Payment of exercise price or tax liability
|
Direct |
451
-3.38%
|
$28,864
$64.92 P/Share
|
|
May 08
2024
|
Harish Manwani Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+14.78%
|
-
|
|
Apr 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-1.11%
|
$10,270
$65.27 P/Share
|
|
Apr 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
515
+3.48%
|
-
|
|
Apr 01
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.03%
|
$144,000
$72.96 P/Share
|